
Novo Nordisk Stock Jumps 24.9% After Closing Cell Therapy Unit and Licensing Parkinson's Program to AI Partner
Novo Nordisk's decision to shutter its internal cell therapy unit and hand its Parkinson's program to AI-enabled Cellular Intelligence triggered a 24.9% stock surge, signalling market approval for asset-light, AI-accelerated models. NVIDIA's BioNeMo platform is emerging as the connective infrastructure linking European pharma incumbents to a new generation of AI-native drug discovery companies. A concurrent wave of specialised biological foundation models indicates the platform layer is maturing




























